to develop a dry powder inhaled mRNA-based treatment for influenza and Covid. Under the partnership, funded by BARDA and other U.S. government agencies, TFF Pharmaceuticals will test the ...

Researchers from Touro University and Lovelace Biomedical are Developing an Innovative Treatment for Lung Cancer ...

The global aerosol delivery devices market was valued at $31,463.9 million in 2019, and is projected to reach $46,728.7 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Rise in ...

After detailed deliberation, the committee accepted the phase II clinical trial results and agreed to the firm’s proposal to ...

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation ...